Business Context and Reporting Period
Kyntra Bio, Inc. (KYNB) filed a Form 8-K on April 2, 2026, reporting a notice received from the Nasdaq Listing Qualifications Staff regarding non-compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. It notes that the company failed to meet the $50 million threshold for total assets and total revenue for the most recently completed fiscal year (or two of the last three) under Listing Rule 5450(b)(3)(A).
Material Changes
- Non-Compliance Trigger: The failure to meet listing requirements is attributed to the revenue of FibroGen International being classified as "held for sale" (discontinued operations) in 2024 and 2025.
- Alternative Standards: The company currently does not meet the alternative listing requirements for shareholders' equity or market value of listed securities.
Outlook, Risks, and Management Commentary
- Immediate Status: The notification has no immediate effect on the listing of Kyntra Bio's common stock on the Nasdaq Global Select Market.
- Compliance Timeline: The company has 45 days (until May 18, 2026) to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 days (until September 29, 2026) to evidence compliance.
- Strategic Options: The company may submit a plan demonstrating compliance with stockholders' equity or market value standards. Additionally, Kyntra Bio may consider transferring its securities to the Nasdaq Capital Market.
- Review Factors: Nasdaq will consider the likelihood of compliance, past history, reasons for non-compliance, other corporate events, financial condition, and public disclosures when evaluating the plan.
Investor Verification Checklist
- Verify the specific financial impact of classifying FibroGen International as "held for sale" on total assets and revenue.
- Monitor the submission of the compliance plan by the May 18, 2026 deadline.
- Assess the likelihood of Nasdaq accepting the plan or granting an extension.
- Track any potential announcement regarding a transfer to the Nasdaq Capital Market.
- Review upcoming filings for updates on shareholders' equity and market value of listed securities.